Literature DB >> 11104555

Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).

J Donadieu1, M F Auclerc, A Baruchel, Y Perel, P Bordigoni, J Landman-Parker, T Leblanc, G Cornu, D Sommelet, G Leverger, G Schaison, C Hill.   

Abstract

Many cutpoints have been proposed to categorize continuous variables in childhood acute lymphoblastic leukaemia (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age), and have been used to define therapeutic subgroups. This variation in the choice of cutpoints leads to a bias called the 'Will Rogers phenomenon'. The aim of this study was to analyse variations in the relative risk of relapse or death as a function of continuous prognostic variables in childhood ALL and to discuss the choice of cutpoints. We studied a population of 1545 children with ALL enrolled in three consecutive protocols named FRALLE 83, FRALLE 87 and FRALLE 89. We estimated the risk of relapse or death associated with different values of each continuous prognostic variable by dividing the sample into quintiles of the distribution of the variables. As regards age, a category of children under 1 year of age was distinguished and the rest of the population was divided into quintiles. The floated variance method was used to calculate the confidence interval of each relative risk, including the reference category. The relation between the quantitative prognostic factors and the risk was monotonic for each variable, except for age. For the white blood cell count (WBC), the relation is log linear. The risk associated with WBC values in the upper quintile was 1.9 times higher than that in the lower quintile. The peripheral blast cell count correlated strongly with WBC (correlation coefficient: 0.99). The risk increased with the haemoglobin level, and the risk in the upper quintile was 1.3 times higher than that in the lower quintile. The risk decreased as the platelet count increased: the risk in the lower quintile was 1.2 times higher than that in the upper quintile. The risk increased gradually with increasing age above one year. The small subgroup of patients (2.5% of the population) under 1 year of age at diagnosis had a risk 2.6 times higher than the reference category of patients between 3 and 4.3 years of age. When the risk associated with a quantitative prognostic factor varies monotonously, the selection of a cutpoint is arbitrary and represents a loss of information. Despite this loss of information, such arbitrary categorization may be necessary to define therapeutic stratification. In that case, consensus cutpoints must be defined if one wants to avoid the Will Rogers phenomenon. The cutpoints proposed by the Rome workshop and the NCI are arbitrary, but may represent an acceptable convention. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104555      PMCID: PMC2363446          DOI: 10.1054/bjoc.2000.1504

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  IMPLICATIONS OF LONG-TERM SURVIVAL IN ACUTE STEM CELL LEUKEMIA OF CHILDHOOD TREATED WITH COMPOSITE CYCLIC THERAPY.

Authors:  W W ZUELZER
Journal:  Blood       Date:  1964-11       Impact factor: 22.113

2.  Treatment of acute lymphoblastic leukemia: protocol Fralle 83-85.

Authors:  G Schaison; D Olive; G Leverger; J P Vannier; L de Lumley; A Bancillon; G Cornu
Journal:  Haematol Blood Transfus       Date:  1990

3.  The staging of childhood acute lymphoblastic leukemia: strategies of the Childrens Cancer Study Group and a three-dimensional technic of multivariate analysis.

Authors:  W A Bleyer; H Sather; P Coccia; J Lukens; S Siegel; G D Hammond
Journal:  Med Pediatr Oncol       Date:  1986

4.  The problem of "staging" in childhood acute lymphoblastic leukemia: a review.

Authors:  R Mastrangelo
Journal:  Med Pediatr Oncol       Date:  1986

5.  Prognosis and treatment of acute lymphoblastic leukemia. Study of 650 patients.

Authors:  C Jacquillat; M Weil; M F Auclerc; C Chastang; G Flandrin; V Izrael; G Schaison; L Degos; M Boiron; J Bernard
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

6.  Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment.

Authors:  R Mastrangelo; D Poplack; A Bleyer; R Riccardi; H Sather; G D'Angio
Journal:  Med Pediatr Oncol       Date:  1986

7.  [Acute lymphoblastic leukemia in infancy: results of 5 multicenter ALL-BFM therapy studies 1970-1986].

Authors:  P Bucsky; A Reiter; J Ritter; R Dopfer; H Riehm
Journal:  Klin Padiatr       Date:  1988 May-Jun       Impact factor: 1.349

8.  [Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81].

Authors:  M Schrappe; J Beck; W E Brandeis; H J Feickert; H Gadner; N Graf; W Havers; G Henze; A Jobke; B Kornhuber
Journal:  Klin Padiatr       Date:  1987 May-Jun       Impact factor: 1.349

9.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

Authors:  A R Feinstein; D M Sosin; C K Wells
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

Review 10.  Remaining problems in the staging and treatment of childhood lymphoblastic leukemia.

Authors:  W A Bleyer
Journal:  Am J Pediatr Hematol Oncol       Date:  1989
View more
  6 in total

1.  Canine acute leukaemia: 50 cases (1989-2014).

Authors:  A L Bennett; L E Williams; M W Ferguson; M L Hauck; S E Suter; C B Lanier; P R Hess
Journal:  Vet Comp Oncol       Date:  2016-07-12       Impact factor: 2.613

2.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

Authors:  Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

Review 3.  Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

Authors:  Joël Schlatter; David Nguyen; Michèle Zamy; Sofiane Kabiche; Jean-Eudes Fontan; Salvatore Cisternino
Journal:  Eur Spine J       Date:  2017-11-18       Impact factor: 3.134

4.  Cyr61 participates in the pathogenesis of acute lymphoblastic leukemia by enhancing cellular survival via the AKT/NF-κB signaling pathway.

Authors:  Xianjin Zhu; Yanfang Song; Conglian Wu; Chuxi Pan; Pingxia Lu; Meihua Wang; Peizheng Zheng; Rongfen Huo; Chenqing Zhang; Wanting Li; Yulin Lin; Yingping Cao; Ningli Li
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

5.  Clinical features and outcome of pediatric acute lymphoblastic leukemia with low peripheral blood blast cell count at diagnosis.

Authors:  Qingkai Dai; Ge Zhang; Hui Yang; Yuefang Wang; Lei Ye; Luyun Peng; Rui Shi; Siqi Guo; Jiajing He; Yongmei Jiang
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

6.  Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia.

Authors:  Qingkai Dai; Rui Shi; Ge Zhang; Hui Yang; Yuefang Wang; Lei Ye; Luyun Peng; Siqi Guo; Jiajing He; Yongmei Jiang
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.